New Therapy Could Target One of the Deadliest Brain Cancers

New Therapy Could Target One of the Deadliest Brain Cancers focuses on an experimental approach to glioblastoma, described as among the most lethal brain cancers. Researchers say they developed a therapy that exploits a vulnerability in the disease, with results published in Nature. The treatment remains years from patient use and has been tested only in preclinical models so far. The article notes that most glioblastoma patients survive about 12 to 18 months after diagnosis, with roughly 5% living beyond five years. The study’s authors argue glioblastoma behaves more like an ecosystem than an isolated mass, relying on networks of surrounding cells. They identify the protein GPNMB on both tumor cells and tumor-associated macrophages, then engineer CAR-T cells to recognize GPNMB wherever it appears. The goal is to disrupt cancer and supportive immune components simultaneously.